Tesetaxel

DRUG11 trials

Conditions

Adenocarcinoma of Esophagogastric JunctionAdenocarcinoma of the StomachAdvanced MelanomaAdvanced Solid TumorsBreast CancerCancerCarcinoma, Transitional CellGastric Carcinoma

Phase 1

Study of Tesetaxel in Japanese Patients With Solid Tumors

NCT01337310

Genta IncorporatedAdvanced Solid Tumors

Start: 2011-04-30End: 2012-09-30Target: 12Updated: 2012-03-13

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

TerminatedNCT04312282

Odonate Therapeutics, Inc.Advanced Solid Tumors

Start: 2020-03-06End: 2021-06-15Updated: 2021-07-28

Phase 2

Phase II Study of Tesetaxel in Metastatic Melanoma

CompletedNCT01064713

M.D. Anderson Cancer CenterAdvanced Melanoma, Cancer

Start: 2010-02-28End: 2014-10-31Updated: 2018-07-17

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

NCT01092585

Genta IncorporatedMelanoma

Start: 2010-02-28End: 2012-03-31Target: 27Updated: 2011-11-08

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

NCT01095120

Genta IncorporatedAdenocarcinoma of Esophagogastric Junction, Adenocarcinoma of the Stomach

Start: 2010-03-31End: 2012-10-31Target: 27Updated: 2012-03-15

Tesetaxel for Previously Treated Patients With Bladder Cancer

NCT01215877

Genta IncorporatedCarcinoma, Transitional Cell

Start: 2010-09-30End: 2012-12-31Target: 33Updated: 2012-07-11

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

NCT01296243

Genta IncorporatedProstate Cancer

Start: 2011-02-28End: 2015-02-28Target: 57Updated: 2012-07-24

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

NCT01573468

Genta IncorporatedGastric Carcinoma

Start: 2012-04-30End: 2014-08-31Target: 580Updated: 2012-07-24

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

NCT01609127

Genta IncorporatedLocally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer

Start: 2012-05-31End: 2014-07-31Target: 213Updated: 2012-06-01

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

TerminatedNCT03858972

Odonate Therapeutics, Inc.Breast Cancer

Start: 2019-02-05End: 2021-06-11Updated: 2021-07-30

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

TerminatedNCT03952325

Odonate Therapeutics, Inc.Breast Cancer

Start: 2019-07-09End: 2021-06-23Updated: 2021-07-30

Related Papers

Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.

Journal of Clinical Oncology2021-05-201 citations

CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC).

Journal of Clinical Oncology2020-05-203 citations

Abstract OT1-08-08: CONTESSA TRIO: A multinational, multicenter, phase 2 study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with HER2- metastatic breast cancer (MBC)

Cancer Research2020-02-15

Abstract OT1-08-07: CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane